Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trial Sharon E Cox, PhD, Elizabeth A Ellins, PhD, Alphonce I Marealle, MSc, Prof Charles R Newton, MD Res, Deogratias Soka, MB, Philip Sasi, PhD, Gian Luca Di Tanna, PhD, William Johnson, PhD, Julie Makani, PhD, Prof Andrew M Prentice, PhD, Prof Julian P Halcox, MD Res, Prof Fenella J Kirkham, MD Res The Lancet Haematology Volume 5, Issue 4, Pages e147-e160 (April 2018) DOI: 10.1016/S2352-3026(18)30020-6 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 1 Trial profile (A) Trial profile. (B) Timeline. RUSF=ready-to-use supplementary food. RUSF-v=vascular treatment. RUSF-b=basic food. *One participant had missing endothelial data. The Lancet Haematology 2018 5, e147-e160DOI: (10.1016/S2352-3026(18)30020-6) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 2 Anthropometry at each clinic visit Data are mean ± 95% CI. At each timepoint: (A) height-for-age Z-scores; (B) weight-for-age Z-scores; (C) body-mass index-for-age Z-scores; (D) body mass, stratified by sex; and (E) body fat, stratified by sex. The Lancet Haematology 2018 5, e147-e160DOI: (10.1016/S2352-3026(18)30020-6) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions